Ionis Pharmaceuticals Inc (NAS:IONS)
$ 38.8 -0.28 (-0.72%) Market Cap: 5.66 Bil Enterprise Value: 4.94 Bil PE Ratio: 0 PB Ratio: 19.11 GF Score: 74/100

Ionis Pharmaceuticals Inc at TD Cowen RNA Therapeutics Summit (Virtual) Transcript

Jul 10, 2023 / 02:25PM GMT
Release Date Price: $41.78
Yaron Benjamin Werber
TD Cowen, Research Division - MD & Senior Biotechnology Analyst

Well, good morning, everybody, and thank you for joining us for our 2nd RNA Summit. I'm Yaron Werber, on the biotech team here at TD Cowen, and it's a great pleasure to moderate the next session with Ionis Pharmaceuticals with Brett Monia, who is the Chief Executive Officer.

Brett, good morning. Right and early on your side. Thanks for joining us.

Brett P. Monia
Ionis Pharmaceuticals, Inc. - Founder, CEO & Director

Good morning, Yaron. it's a pleasure to be here.

Questions & Answers

Yaron Benjamin Werber
TD Cowen, Research Division - MD & Senior Biotechnology Analyst

So lots to talk about. I want to kick off with eplontersen, especially on the heels of the 85 week data was literally which just got presented showing a nice sustainability now we've seen from 35 weeks to 66 weeks, and now to 85 weeks on TTR reduction and clinical outcomes as well. The PDUFA is coming up in December for TTR

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot